Tarbox Family Office’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Tarbox Family Office’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$7K	–	1201
2021 Q3	$7K	Sell	2,000 -1,000	-33%	-$3.5K	﹤0.01%	574
2021 Q2	$13K	Buy	+3,000	New	+$12.7K	﹤0.01%	450

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tarbox Family Office's CNCE Position: Q4 2021 in Review

Tarbox Family Office sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 2,000 shares — an estimated $7K sold.

Tarbox Family Office first reported a position in CNCE in Q2 2021 and held it in 2 quarters. The position peaked at $13K in Q2 2021. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

Tarbox Family Office reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Tarbox Family Office sold 2,000 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $7K.
Tarbox Family Office first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
Tarbox Family Office's Concert Pharmaceuticals, Inc. position peaked at $13K in Q2 2021.
52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on Tarbox Family Office's 13F filing for Q4 2021, filed 6 Jan 2022.